Roivant Sciences Ltd (NASDAQ: ROIV) on Tuesday, plunged -1.01% from the previous trading day, before settling in for the closing price of $10.87. Within the past 52 weeks, ROIV’s price has moved between $8.73 and $13.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 29.37%. The company achieved an average annual earnings per share of -109.96%. With a float of $438.43 million, this company’s outstanding shares have now reached $719.63 million.
Let’s determine the extent of company efficiency that accounts for 908 employees. In terms of profitability, gross margin is 89.03%, operating margin of -1027.4%, and the pretax margin is -594.75%.
Roivant Sciences Ltd (ROIV) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Roivant Sciences Ltd is 38.56%, while institutional ownership is 67.84%. The most recent insider transaction that took place on May 20 ’25, was worth 1,095,000. In this transaction President & COO of this company sold 100,000 shares at a rate of $10.95, taking the stock ownership to the 1,077,197 shares. Before that another transaction happened on May 20 ’25, when Company’s Officer proposed sale 100,000 for $10.95, making the entire transaction worth $1,094,986.
Roivant Sciences Ltd (ROIV) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -109.96% per share during the next fiscal year.
Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators
Roivant Sciences Ltd (ROIV) is currently performing well based on its current performance indicators. A quick ratio of 37.91 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 78.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.14, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -1.12 in one year’s time.
Technical Analysis of Roivant Sciences Ltd (ROIV)
Looking closely at Roivant Sciences Ltd (NASDAQ: ROIV), its last 5-days average volume was 3.44 million, which is a drop from its year-to-date volume of 5.7 million. As of the previous 9 days, the stock’s Stochastic %D was 52.23%. Additionally, its Average True Range was 0.31.
During the past 100 days, Roivant Sciences Ltd’s (ROIV) raw stochastic average was set at 58.50%, which indicates a significant increase from 26.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.09% in the past 14 days, which was lower than the 34.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.60, while its 200-day Moving Average is $11.27. However, in the short run, Roivant Sciences Ltd’s stock first resistance to watch stands at $10.94. Second resistance stands at $11.11. The third major resistance level sits at $11.21. If the price goes on to break the first support level at $10.66, it is likely to go to the next support level at $10.56. Should the price break the second support level, the third support level stands at $10.39.
Roivant Sciences Ltd (NASDAQ: ROIV) Key Stats
Market capitalization of the company is 7.68 billion based on 713,549K outstanding shares. Right now, sales total 124,800 K and income totals 4,349 M. The company made 9,020 K in profit during its latest quarter, and 169,380 K in sales during its previous quarter.
